ATE499111T1 - Zusammensetzungen und verfahren zur oxalatreduktion - Google Patents

Zusammensetzungen und verfahren zur oxalatreduktion

Info

Publication number
ATE499111T1
ATE499111T1 AT06845574T AT06845574T ATE499111T1 AT E499111 T1 ATE499111 T1 AT E499111T1 AT 06845574 T AT06845574 T AT 06845574T AT 06845574 T AT06845574 T AT 06845574T AT E499111 T1 ATE499111 T1 AT E499111T1
Authority
AT
Austria
Prior art keywords
compositions
oxalate
hyperoxaluria
methods
disease
Prior art date
Application number
AT06845574T
Other languages
English (en)
Inventor
Qingshan Li
Harmeet Sidhu
Original Assignee
Oxthera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxthera Inc filed Critical Oxthera Inc
Application granted granted Critical
Publication of ATE499111T1 publication Critical patent/ATE499111T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/488—Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/03—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with oxygen as acceptor (1.2.3)
    • C12Y102/03004—Oxalate oxidase (1.2.3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y208/00—Transferases transferring sulfur-containing groups (2.8)
    • C12Y208/03—CoA-transferases (2.8.3)
    • C12Y208/03016—Formyl-CoA transferase (2.8.3.16)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/23—Aspartic endopeptidases (3.4.23)
    • C12Y304/23002—Pepsin B (3.4.23.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01002—Oxalate decarboxylase (4.1.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01008—Oxalyl-CoA decarboxylase (4.1.1.8)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
AT06845574T 2005-12-16 2006-12-15 Zusammensetzungen und verfahren zur oxalatreduktion ATE499111T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75089605P 2005-12-16 2005-12-16
PCT/US2006/047967 WO2007075447A2 (en) 2005-12-16 2006-12-15 Compositions and methods for oxalate reduction

Publications (1)

Publication Number Publication Date
ATE499111T1 true ATE499111T1 (de) 2011-03-15

Family

ID=38218470

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06845574T ATE499111T1 (de) 2005-12-16 2006-12-15 Zusammensetzungen und verfahren zur oxalatreduktion

Country Status (11)

Country Link
US (2) US8900575B2 (de)
EP (2) EP2366402A1 (de)
JP (1) JP5558002B2 (de)
CN (3) CN107638563A (de)
AT (1) ATE499111T1 (de)
AU (1) AU2006329844B2 (de)
CA (1) CA2633238A1 (de)
DE (1) DE602006020347D1 (de)
ES (1) ES2362897T3 (de)
HK (2) HK1128613A1 (de)
WO (1) WO2007075447A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486389B2 (en) 1997-05-23 2013-07-16 Oxthera, Inc. Compositions and methods for treating or preventing oxalate-related disease
EP2366402A1 (de) 2005-12-16 2011-09-21 OxThera, Inc., Zusammensetzungen und Verfahren zur Oxalatreduktion
US8142775B2 (en) 2006-08-02 2012-03-27 Althea Technologies, Inc. Crystallized oxalate decarboxylase and methods of use
CN101554237B (zh) * 2009-03-16 2013-11-06 武汉康复得生物科技有限公司 植物纤维或微生物不溶组分中的草酸降解酶的制备方法
US8431122B2 (en) * 2009-07-02 2013-04-30 Oxthera Intellectual Property Ab Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes
CA2767039C (en) * 2009-07-02 2018-09-04 Oxthera Intellectual Property Ab Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes
EP2270138B1 (de) * 2009-07-02 2018-03-28 OxThera Intellectual Property AB Reinigung und Isolierung von rekombinanten Oxalat abbauenden Enzymen
AU2010324830B2 (en) * 2009-11-25 2016-04-14 Oxidien Pharmaceuticals, Llc Methods and compositions for treating oxalate-related conditions
CA2831535C (en) * 2011-04-07 2014-10-21 Histapharm Inc. Oral enzyme compositions for intestinal delivery
US9714456B2 (en) 2013-01-18 2017-07-25 Allena Pharmaceuticals, Inc. Crystallized oxalate decarboxylase and methods of use
US11077238B2 (en) 2013-06-07 2021-08-03 Allena Pharmaceuticals, Inc. Compositions, methods, and devices for dialysis
WO2016161455A2 (en) * 2015-04-02 2016-10-06 Captozyme, Llc High efficiency oxalate-degrading enzymes for degradation of insoluble and soluble oxalate
US10765709B2 (en) 2016-06-13 2020-09-08 Oxthera Intellectual Property Compositions and methods for the treatment or prevention of oxalate-related disorders
CN111315812B (zh) 2017-11-08 2022-11-29 马特利艾斯有限责任公司 原位凝胶化粉末
WO2023039469A1 (en) * 2021-09-09 2023-03-16 Unlocked Labs Inc. Therapeutic engineered microbial cell systems and methods for treating conditions in which oxalate is detrimental
CN116444636B (zh) * 2023-04-17 2024-02-20 西南大学 抑制核盘菌的水稻OsGLP3-6及其应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4205132A (en) 1978-07-17 1980-05-27 Microlife Technics, Inc. Lyophilization of bacteria
DE3030185A1 (de) 1980-08-07 1982-04-08 Kohlbecker, Günther, 3000 Hannover Verfahren zur enzymatischen entfernung von oxalat mittels oxalat-oxidase
DE3204284A1 (de) 1982-02-06 1983-08-18 Kohlbecker, Günther, 3000 Hannover Verfahren zur enzymatischen entfernung von sauerstoff
JPS5968344A (ja) 1982-10-12 1984-04-18 Agency Of Ind Science & Technol 非対称機能膜及びその製法
US4539118A (en) 1984-03-23 1985-09-03 Sigma Chemical Company Rapid, accurate method of separation of oxalate from urine and other biological fluids
US5263992A (en) 1986-10-17 1993-11-23 Bio-Metric Systems, Inc. Biocompatible device with covalently bonded biocompatible agent
US5427935A (en) * 1987-07-24 1995-06-27 The Regents Of The University Of Michigan Hybrid membrane bead and process for encapsulating materials in semi-permeable hybrid membranes
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US5286495A (en) 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
RO112764B1 (ro) 1992-11-30 1997-12-30 Zeneca Ltd Secventa adn ce codifica oxalat decarboxilaza
AU6701694A (en) 1993-04-16 1994-11-08 Mccormick & Company, Inc. Encapsulation compositions
US5554147A (en) 1994-02-01 1996-09-10 Caphco, Inc. Compositions and devices for controlled release of active ingredients
US5788687A (en) 1994-02-01 1998-08-04 Caphco, Inc Compositions and devices for controlled release of active ingredients
US5505713A (en) 1994-04-01 1996-04-09 Minimed Inc. Indwelling catheter with stable enzyme coating
WO1995031537A1 (en) 1994-05-18 1995-11-23 Human Genome Sciences, Inc. HUMAN OXALYL-CoA DECARBOXYLASE
US6090628A (en) 1994-06-20 2000-07-18 University Of Florida Materials and methods for detection of Oxalobactor formigenes
US5912125A (en) 1994-06-20 1999-06-15 University Of Florida Materials and methods for detection of oxalobacter
US6214980B1 (en) 1994-06-20 2001-04-10 University Of Florida Materials and methods for detection of Oxalobacte formigenes
US5604111A (en) 1994-06-20 1997-02-18 University Of Florida Research Foundation Method and kit for detection of oxalate
US5916790A (en) * 1995-03-03 1999-06-29 Metabolex, Inc. Encapsulation compositions, and methods
US6033719A (en) 1996-04-25 2000-03-07 Medtronic, Inc. Method for covalent attachment of biomolecules to surfaces of medical devices
SE9603029D0 (sv) 1996-08-20 1996-08-20 Svenska Traeforskningsinst Method for lowering the level of oxalic acid
US7435425B2 (en) * 2001-07-17 2008-10-14 Baxter International, Inc. Dry hemostatic compositions and methods for their preparation
JP4335316B2 (ja) * 1996-09-19 2009-09-30 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン アルギネートまたは修飾アルギネートのようなポリサッカライドを含むポリマー
US6297425B1 (en) 1997-03-21 2001-10-02 Pioneer Hi-Bred International, Inc. Gene encoding oxalate decarboxylase from aspergillus phoenices
EP2033651A1 (de) * 1997-05-23 2009-03-11 OxThera, Inc., Oxalate-abbauende Mikroorganismen oder Oxalate-abbauende Enzyme zur Verhütung der Oxalate-verwandten Krankheiten
US20040120941A1 (en) * 1997-05-23 2004-06-24 Allison Milton J. Materials and methods for treating or preventing oxalate-related disease
US8486389B2 (en) 1997-05-23 2013-07-16 Oxthera, Inc. Compositions and methods for treating or preventing oxalate-related disease
US6355242B1 (en) 1997-05-23 2002-03-12 Ixion Biotechnology, Inc. Materials and methods for treating or preventing oxalate-related disease
US6161499A (en) * 1997-07-07 2000-12-19 Cvd Diamond Corporation Apparatus and method for nucleation and deposition of diamond using hot-filament DC plasma
US6080404A (en) 1997-09-05 2000-06-27 University Of Florida Materials and methods for removal of substances from fluids
US6566407B2 (en) 1997-11-05 2003-05-20 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US5985938A (en) 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
CA2323759A1 (en) * 1998-04-24 1999-11-04 Onyx Pharmaceuticals, Inc. Novel nucleic acids and polypeptides related to a farnesyl-directed cysteine carboxymethyltransferase
CN100358509C (zh) 1998-09-28 2008-01-02 沃纳-兰伯特公司 采用hpmc胶囊进行肠和结肠传递
AR020729A1 (es) 1998-10-09 2002-05-29 Gen Mills Marketing Inc Un metodo para el encapsulado de componentes sensibles en una matriz para obtener particulas discretas y estables durante su almacenamiento
IT1309427B1 (it) 1999-05-28 2002-01-23 Mendes S U R L Composizione dietetica o farmaceutica utile per la prevenzione o iltrattamento dell'iperossaluria e suo uso
MXPA01012658A (es) 1999-06-07 2003-10-15 Nanosphere Inc Metodos para recubrir particulas, y particulas producidas mediante los mismos.
JP5186077B2 (ja) 2000-12-18 2013-04-17 プロバイオヘルス・エルエルシー ラクトバシラス−カゼイｋｅ０１株から得られたプロバイオティック化合物
US7407668B2 (en) 2002-01-24 2008-08-05 Boston Scimed, Inc. Medical articles having enzymatic surfaces for localized therapy
US6929940B1 (en) 2002-08-20 2005-08-16 University Of Florida Research Foundation, Inc. Polynucleotides encoding oxalate decarboxylase from Aspergillus niger and methods of use
NL1021879C2 (nl) * 2002-11-08 2004-05-11 Univ Delft Tech Werkwijze voor het bereiden van vernette enzymdeeltjes.
WO2005060937A1 (en) 2003-12-23 2005-07-07 Chr. Hansen A/S Compressed tablets comprising viable probiotic microorganisms
US20080317810A1 (en) * 2004-05-07 2008-12-25 Harmeet Sidhu Methods and Compositions for Reducing Oxalate Concentrations
JP5047190B2 (ja) 2005-12-14 2012-10-10 オクセラ インコーポレイテッド シュウ酸塩関連疾患を治療または予防するための医薬組成物および方法
EP2366402A1 (de) 2005-12-16 2011-09-21 OxThera, Inc., Zusammensetzungen und Verfahren zur Oxalatreduktion
US8142775B2 (en) 2006-08-02 2012-03-27 Althea Technologies, Inc. Crystallized oxalate decarboxylase and methods of use
US8431122B2 (en) 2009-07-02 2013-04-30 Oxthera Intellectual Property Ab Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes

Also Published As

Publication number Publication date
JP5558002B2 (ja) 2014-07-23
WO2007075447A2 (en) 2007-07-05
AU2006329844A1 (en) 2007-07-05
JP2009519950A (ja) 2009-05-21
CA2633238A1 (en) 2007-07-05
HK1201151A1 (en) 2015-08-28
US20070184118A1 (en) 2007-08-09
AU2006329844B2 (en) 2012-11-15
DE602006020347D1 (de) 2011-04-07
EP1976553B1 (de) 2011-02-23
EP1976553A2 (de) 2008-10-08
EP1976553A4 (de) 2009-09-23
CN107638563A (zh) 2018-01-30
CN101405022A (zh) 2009-04-08
HK1128613A1 (en) 2009-11-06
EP2366402A1 (de) 2011-09-21
US10272043B2 (en) 2019-04-30
US8900575B2 (en) 2014-12-02
WO2007075447A3 (en) 2008-12-24
ES2362897T3 (es) 2011-07-14
US20150125538A1 (en) 2015-05-07
AU2006329844A8 (en) 2008-07-31
CN104013581A (zh) 2014-09-03

Similar Documents

Publication Publication Date Title
ATE499111T1 (de) Zusammensetzungen und verfahren zur oxalatreduktion
HK1110510A1 (en) Probiotic bacteria based composition and use thereof in the prevention and/or treatment of respiratory pathologies and/or infections and in the improvement of the intestinal functionality
ZA200801706B (en) Methods and compositions for the prevention and treatment of kidney disease
BRPI0616960B8 (pt) uso de lactobacilo para o tratamento de infecções virais
MA30250B1 (fr) Vaccins destines a lutter contre une infection a chlamydia
WO2008043107A3 (en) Use of tight junction antagonists to treat inflammatory bowel disease
BRPI0807046A2 (pt) Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit.
BRPI0711901A2 (pt) Composições e métodos para a liberação de oxigênio
BRPI0817063A2 (pt) "métodos de inibição, para o tratamento de uma condição patológica, para a inibição de linfagiogênese tumoral, de inibição ou prevenção,de desorganização, para inibição de crescimento de tumor, de tratamento, de acentuação da eficácia de um agente anti-angiogênese e antagonista de alk-1
ZA200800452B (en) Methods and compositions for the prevention and treatment of kidney disease
WO2010115092A3 (en) Compositions and methods for treating or preventing inflammatory bowel disease and colon cancer
CL2007003332A1 (es) Compuestos derivados de heterociclos condensados; compuestos intermediarios; composicion farmaceutica; y uso en la prevencion o tratamiento de infecciones bacterianas.
PL1732575T3 (pl) Związki zawierające stron do stosowania w zapobieganiu lub leczeniu stanów nekrotycznych kości
EP1874130A4 (de) Verfahren und zusammensetzungen für die vorbeugung und behandlung von nierenerkrankungen
IL189270A0 (en) Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
ZA200800448B (en) Methods and compositions for the prevention and treatment of inflammatory disease
BRPI0610722A2 (pt) métodos para tratar uma infecção bacteriana, para prevenir, tratar ou melhorar o tratamento eficaz de mrsa, para inibir o crescimento de um micróbio, e para selecionar um agente terapêutico de mrsa útil pata tratar uma infcção bacteriana, e, composição
BRPI1010837A2 (pt) prevenção e tratamento de diarreia alérgica
EP2666480A3 (de) Anwendungen und Zusammensetzungen zur Behandlung von Morbus Crohn
WO2009042642A3 (en) Compositions and methods for the treatment and prevention of ulcerative colitis and colon cancer
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
IL186672A0 (en) Phosphonated fluoroquinolones, antibacterial analogs thereof, and methods for the prevention and treatment of bone and joint infections
WO2007139970A3 (en) Men1 gene for diagnosis and treatment of diabetes
WO2010065085A3 (en) Methods and compositions for treating or preventing pruritis
ATE544856T1 (de) Peptid- und nukleotidsequenzen von anisakis spp. und ihre verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties